- Home
- News
- us virgislands
- clinical support
Refine by
Clinical Support Articles & Analysis
371 news found
Bremen, Germany – May 4, 2026 — Kerecis, the company pioneering the use of sustainably sourced intact fish skin in cellular therapy and tissue regeneration, will play a prominent scientific and educational role at EWMA-DEWU 2026 Conference, taking place May 6–8 at the Messe & Congress Centrum Bremen in Bremen, Germany.This year EWMA, The European Wound Management Association meeting, is held in ...
ByKerecis
It references commercially available fish-skin-derived regenerative wound products for their demonstrated potential to support healing, reduce complications, and contribute to limb-sparing treatment strategies, and urges the VHA to promote greater consistency in formulary access and clinical availability across VA medical centers and VISNs.Kerecis’ intact ...
ByKerecis
Kerecis will highlight its intact fish-skin platform and new clinical data at SAWC Spring 2026, taking place April 8–11 at the Charlotte Convention Center. ...
ByKerecis
BC Platforms has embedded NVIDIA accelerated computing into BC Mosaic, its trusted research environment, enabling faster GPU-powered analytics and AI-led analyses across clinical, multi-omics, and real-world data to support precision medicine and accelerated drug development.NVIDIA integration in BC MosaicNVIDIA technology is now natively available within BC ...
Precision is supporting the POTENTIATE clinical trial by adapting its diagnostic workflow to ensure a seamless connection with the SOPHiA DDM™ Platform. ...
Having earned a strong reputation for its expertise in GLP services, Protheragen-ING Lab offers a wide range of preclinical and clinical services to support drug development. The launch of Protheragen-ING Lab's medical device services marks a significant milestone in the company's evolution, further solidifying its position as a leader in the life sciences ...
Together, Tris Pharma and Perigon launched a direct-to-patient program, DYANAVEL Delivered, that allows patients and caregivers to seamlessly access DYANAVEL XR extended-release tablets through Perigon’s digital pharmacy, enhance their medication management, and receive reimbursement assistance and support to help navigate their treatment journey while reducing ...
CELLINK, a global leader in bioprinting technologies, is proud to announce a pioneering innovation in the field of regenerative medicine and tissue engineering with the launch of CELLINK Vivoink, the first-ever medical-grade bioink specially designed to support researchers on their clinical translational journey. CELLINK Vivoink is optimized for superior ...
ByCELLINK
She is a qualified adult nurse and has previously held operational leadership roles including, registered manager, regional support manager, regional clinical quality manager, head of quality and director of health. Lindsay is an experienced professional who brings with her expertise in commercial operational leadership, clinical governance , ...
Naturally present in milk as part of the milk fat globule membrane (MFGM), phospholipids are complex lipids clinically shown to support a range of mental health benefits, including staying positive and focused under stress, said Shakti Singh, PhD, technical engagement manager, active living for Fonterra. ...
It is a well-respected heart health research institute, which also participates in clinical trials targeting new ways to manage, prevent and cure cardiovascular disease. ...
The company is already advancing multiple novel biology, first-in-class programs towards the clinic and has more than a dozen similar pipeline opportunities emerging in early discovery. In his new role, Jeffrey Hatfield will continue to take an active role in the growth and maturation of Vividion towards a clinical-stage company, providing guidance and ...
ByBayer AG
Funding from the Series B will allow Oligomerix to accelerate its transition into Phase 1 human clinical development planned for early 3Q 2022. Oligomerix closes Series B extension to accelerate transition into Phase 1 human clinical development. ...
The duration of the full ALS visit will be approximately 17 hours. Subjects will have an in-clinic safety follow-up visit within seven days after the full ALS visit. ...
Targeting peak sales potential of $1 billion in the major markets Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, is pleased to announce that it has now finalised plans for its Phase 3 studies for its late-stage clinical asset, XF-73 ...
” Jeremy Sobotta, Perimeter’s Chief Executive Officer commented, “This publication further supports the potential use of our flagship Perimeter S-Series OCT medical imaging technology across several tissue types, including head and neck surgery. Further, this clinical research shows that the Perimeter OCT images correlate to histological ...
“Emergent is pleased to gain the support of the CDMRP to verify the clinical benefit of our CHIKV VLP vaccine candidate for CHIKV disease through a post-approval field efficacy study,” said Chris Cabell, M.D., chief medical officer and SVP clinical development at Emergent BioSolutions. ...
For nearly 16 years, she worked for CureVac, the global biopharmaceutical company and took responsibility as Chief Scientific and Chief Technology Officer. Her revolutionary work has supported multiple clinical trials with cancer therapies, prophylactic vaccines, and development of antibody therapies. ...
ByArdigen
The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that is currently being evaluated in a pivotal clinical trial, with support from a grant of up to US$7.4 million awarded by the Cancer Prevention and Research Institute of Texas. ...
Destiny Pharma will continue to work with NIAID to complete this preclinical safety package which will support future clinical development of XF-73 Dermal in serious wound infections. The study is planned to complete in Q2 2023 and should then be ready to move into clinical trials. Neil Clark, CEO of Destiny Pharma, said: “We are very ...